{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:57:45Z","timestamp":1793069865209,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Healthy individuals and patients with cancer who are carriers of germline pathogenic variants in the\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      genes face multiple reproductive challenges that require appropriate counseling and specific expertise.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>On December 5th\u20137th, 2019, patient advocates and physicians with expertise in the field of reproductive medicine, fertility preservation, and oncology were invited to \u201cSan Giuseppe Moscati\u201d Hospital in Avellino (Italy) for a workshop on reproductive management of women with germline pathogenic variants in the BRCA1\/2 genes. From the discussion regarding the current evidence and future prospective in the field, eight main research questions were formulated and eight recommendations were developed regarding fertility, fertility preservation, preimplantation genetic testing, and pregnancy in healthy carriers and patients with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Several misconceptions about the topic persist among health care providers and patients often resulting in a discontinuous and suboptimal management. With the aim to offer patient-tailored counseling about reproductive issues, both awareness of current evidences and research should be promoted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-021-02081-7","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T21:02:21Z","timestamp":1631221341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Reproductive issues in carriers of germline pathogenic variants in the BRCA1\/2 genes: an expert meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Barbara","family":"Buonomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Massarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Dellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Anserini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Campanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirosa","family":"Magnotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristofaro","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedro Alessandro","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"2081_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bpobgyn.2020.02.007","volume":"65","author":"O Evans","year":"2020","unstructured":"Evans O, Gaba F, Manchanda R. Population-based genetic testing for Women\u2019s cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2020;65:139\u201353. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.02.007.","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"issue":"23","key":"2081_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"key":"2081_CR3","unstructured":"Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Cardiff (UK): National Collaborating Centre for Cancer (UK); 2013."},{"issue":"Suppl 8","key":"2081_CR4","doi-asserted-by":"publisher","first-page":"viii22","DOI":"10.1093\/annonc\/mdt307","volume":"24","author":"B Pothuri","year":"2013","unstructured":"Pothuri B. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol. 2013;24(Suppl 8):viii22\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdt307.","journal-title":"Ann Oncol"},{"issue":"2","key":"2081_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","volume":"22","author":"S Gonz\u00e1lez-Santiago","year":"2020","unstructured":"Gonz\u00e1lez-Santiago S, Ram\u00f3n Y, Cajal T, Aguirre E, et al. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). Clin Transl Oncol. 2020;22(2):193\u2013200. https:\/\/doi.org\/10.1007\/s12094-019-02262-0.","journal-title":"Clin Transl Oncol."},{"issue":"suppl 5","key":"2081_CR6","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","volume":"27","author":"S Paluch-Shimon","year":"2016","unstructured":"Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016;27(suppl 5):v103\u201310.","journal-title":"Ann Oncol."},{"issue":"5","key":"2081_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.rbmo.2018.11.031","volume":"38","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Di Maio M, Poggio F, et al. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. Reprod Biomed Online. 2019;38(5):835\u201344.","journal-title":"Reprod Biomed Online."},{"issue":"60","key":"2081_CR8","doi-asserted-by":"publisher","first-page":"102110","DOI":"10.18632\/oncotarget.22193","volume":"8","author":"B Park","year":"2017","unstructured":"Park B, Hopper JL, Win AK, et al. Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers. Oncotarget. 2017;8(60):102110\u20138.","journal-title":"Oncotarget."},{"issue":"4","key":"2081_CR9","doi-asserted-by":"publisher","first-page":"pky078","DOI":"10.1093\/jncics\/pky078","volume":"2","author":"MB Terry","year":"2018","unstructured":"Terry MB, Liao Y, Kast K, Antoniou AC, McDonald JA, Mooij TM, et al. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectr. 2018;2(4):pky078. https:\/\/doi.org\/10.1093\/jncics\/pky078.","journal-title":"JNCI Cancer Spectr"},{"issue":"6","key":"2081_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/ijc.21273","volume":"117","author":"CA Cullinane","year":"2005","unstructured":"Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers. Int J Cancer. 2005;117(6):988\u201391. https:\/\/doi.org\/10.1002\/ijc.21273.","journal-title":"Int J Cancer."},{"issue":"1","key":"2081_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7326\/M18-1323","volume":"170","author":"HB Nichols","year":"2019","unstructured":"Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, et al. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. Ann Intern Med. 2019;170(1):22\u201330. https:\/\/doi.org\/10.7326\/M18-1323 Epub 2018 Dec 11.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2081_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/1055-9965.EPI-05-0634","volume":"15","author":"G Albrektsen","year":"2006","unstructured":"Albrektsen G, Heuch I, Thoresen S, Kv\u00e5le G. Clinical stage of breast cancer by parity, age at birth, and time since birth: a progressive effect of pregnancy hormones? Cancer Epidemiol Biomarkers Prev. 2006;15(1):65\u20139. https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0634.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"2","key":"2081_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-018-4822-y","volume":"171","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, et al. Narod SA; Hereditary Breast Cancer Clinical Study Group. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018;171(2):421\u20136. https:\/\/doi.org\/10.1007\/s10549-018-4822-y.","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"2081_CR14","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/bcr3138","volume":"14","author":"J Kotsopoulos","year":"2012","unstructured":"Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42. https:\/\/doi.org\/10.1186\/bcr3138.","journal-title":"Breast Cancer Res."},{"issue":"10017","key":"2081_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(15)01024-7","volume":"387","author":"CG Victora","year":"2016","unstructured":"Victora CG, Bahl R, Barros AJ, Fran\u00e7a GV, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet. 2016;387(10017):475\u201390.","journal-title":"Lancet."},{"issue":"1","key":"2081_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13058-015-0604-1","volume":"17","author":"Y Ram\u00f3n","year":"2015","unstructured":"Ram\u00f3n Y, Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo \u00c1, et al. Mammographic density and breast cancer in women from high risk families. Breast Cancer Res. 2015;17(1):93. https:\/\/doi.org\/10.1186\/s13058-015-0604-1.","journal-title":"Breast Cancer Res."},{"issue":"1","key":"2081_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-013-2729-1","volume":"142","author":"A Valentini","year":"2013","unstructured":"Valentini A, Lubinski J, Byrski T, et al. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013;142(1):177\u201385.","journal-title":"Breast Cancer Res Treat."},{"key":"2081_CR18","doi-asserted-by":"publisher","unstructured":"Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, Poorvu PD, Kim HJ, Villarreal-Garza C, Pistilli B, Vaz-Luis I, Saura C, Ruddy KJ, Franzoi MA, Sertoli C, Ceppi M, Azim HA Jr, Amant F, Demeestere I, Del Mastro L, Partridge AH, Pagani O, Peccatori FA. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021; [ahead of print] doi: https:\/\/doi.org\/10.1200\/JCO.21.00535.","DOI":"10.1200\/JCO.21.00535"},{"issue":"26","key":"2081_CR19","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.19.02399","volume":"38","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, et al. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. J Clin Oncol. 2020;38(26):3012\u201323. https:\/\/doi.org\/10.1200\/JCO.19.02399.","journal-title":"J Clin Oncol."},{"key":"2081_CR20","doi-asserted-by":"publisher","unstructured":"Azim HA Jr, Ameye L, Paesmans M, Lambertini M. Reply to S. Narod et al. J Clin Oncol. 2020;38(36):4352\u20134. https:\/\/doi.org\/10.1200\/JCO.20.02850.","DOI":"10.1200\/JCO.20.02850"},{"issue":"3","key":"2081_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.breast.2015.01.005","volume":"24","author":"O Pagani","year":"2015","unstructured":"Pagani O, Ruggeri M, Manunta S, et al. Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? Breast. 2015;24(3):201\u20137.","journal-title":"Breast."},{"issue":"1","key":"2081_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12958-019-0561-0","volume":"18","author":"X Zhang","year":"2020","unstructured":"Zhang X, Niu J, Che T, Zhu Y, Zhang H, Qu J. Fertility preservation in BRCA mutation carriers-efficacy and safety issues: a review. Reprod Biol Endocrinol. 2020;18(1):11. https:\/\/doi.org\/10.1186\/s12958-019-0561-0.","journal-title":"Reprod Biol Endocrinol."},{"issue":"1","key":"2081_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/humupd\/dmz043","volume":"26","author":"V Turan","year":"2020","unstructured":"Turan V, Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum Reprod Update. 2020;26(1):43\u201357.","journal-title":"Hum Reprod Update."},{"issue":"6","key":"2081_CR24","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.fertnstert.2014.08.014","volume":"102","author":"ET Wang","year":"2014","unstructured":"Wang ET, Pisarska MD, Bresee C, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723\u20138.","journal-title":"Fertil Steril."},{"issue":"4","key":"2081_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jayao.2016.0009","volume":"5","author":"S Giordano","year":"2016","unstructured":"Giordano S, Garrett-Mayer E, Mittal N, et al. Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast\/Ovarian Cancer Risk. J Adolesc Young Adult Oncol. 2016;5(4):337\u201343.","journal-title":"J Adolesc Young Adult Oncol."},{"issue":"5","key":"2081_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/humrep\/dew044","volume":"31","author":"KA Phillips","year":"2016","unstructured":"Phillips KA, Collins IM, Milne RL, et al. Anti-M\u00fcllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126\u201332.","journal-title":"Hum Reprod."},{"issue":"5","key":"2081_CR27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.fertnstert.2017.03.018","volume":"107","author":"L Johnson","year":"2017","unstructured":"Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C. Antim\u00fcllerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017;107(5):1256\u20131265.e6.","journal-title":"Fertil Steril"},{"key":"2081_CR28","doi-asserted-by":"publisher","first-page":"15931","DOI":"10.18632\/oncotarget.24638","volume":"9","author":"I Ben-Aharon","year":"2018","unstructured":"Ben-Aharon I, Levi M, Margel D, Yerushalmi R, Rizel S, Perry S, et al. Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging? Oncotarget. 2018;9:15931\u201341.","journal-title":"Oncotarget."},{"issue":"1","key":"2081_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/ijgc-2019-000626","volume":"30","author":"J Ponce","year":"2020","unstructured":"Ponce J, Fernandez-Gonzalez S, Calvo I, et al. Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers. Int J Gynecol Cancer. 2020;30(1):83\u20138.","journal-title":"Int J Gynecol Cancer."},{"issue":"172","key":"2081_CR30","doi-asserted-by":"publisher","first-page":"172ra21","DOI":"10.1126\/scitranslmed.3004925","volume":"5","author":"S Titus","year":"2013","unstructured":"Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. https:\/\/doi.org\/10.1126\/scitranslmed.3004925 PMID: 23408054; PMCID: PMC5130338.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2081_CR31","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1086\/421442","volume":"74","author":"I Gal","year":"2004","unstructured":"Gal I, Sadetzki S, Gershoni-Baruch R, Oberman B, Carp H, Papa MZ, et al. Offspring gender ratio and the rate of recurrent spontaneous miscarriages in Jewish women at high risk for breast\/ovarian cancer. Am J Hum Genet. 2004;74(6):1270\u20135.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2081_CR32","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/bcr1387","volume":"8","author":"E Friedman","year":"2006","unstructured":"Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006;8(2):R15.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2081_CR33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajhb.20978","volume":"22","author":"R Moslehi","year":"2010","unstructured":"Moslehi R, Singh R, Lessner L, Friedman JM. Impact of BRCA mutations on female fertility and offspring sex ratio. Am J Hum Biol. 2010;22(2):201\u20135.","journal-title":"Am J Hum Biol"},{"issue":"6","key":"2081_CR34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.fertnstert.2008.12.052","volume":"93","author":"T Pal","year":"2010","unstructured":"Pal T, Keefe D, Sun P, Narod SA. Hereditary Breast Cancer Clinical Study Group. Fertility in women with BRCA mutations: a case-control study. Fertil Steril. 2010;93(6):1805\u20138.","journal-title":"Fertil Steril"},{"issue":"1732","key":"2081_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1098\/rspb.2011.1697","volume":"279","author":"KR Smith","year":"2012","unstructured":"Smith KR, Hanson HA, Mineau GP, Buys SS. Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci. 2012;279(1732):1389\u201395. https:\/\/doi.org\/10.1098\/rspb.2011.1697.","journal-title":"Proc Biol Sci."},{"issue":"11","key":"2081_CR36","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1093\/humrep\/dew242","volume":"31","author":"TC van Tilborg","year":"2016","unstructured":"van Tilborg TC, Derks-Smeets IAP, Bos AME, Oosterwijk JC, van Golde RJ, de Die-Smulders CE, et al. Serum AMH levels in healthy women from BRCA1\/2 mutated families: are they reduced? Hum Reprod. 2016;31(11):2651\u20139.","journal-title":"Hum Reprod"},{"issue":"2","key":"2081_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.rbmo.2013.10.007","volume":"28","author":"I Streuli","year":"2014","unstructured":"Streuli I, de Mouzon J, Paccolat C, Chapron C, Petignat P, Irion OP, et al. AMH concentration is not related to effective time to pregnancy in women who conceive naturally. Reprod Biomed Online. 2014;28(2):216\u201324. https:\/\/doi.org\/10.1016\/j.rbmo.2013.10.007 Epub 2013 Oct 23.","journal-title":"Reprod Biomed Online."},{"issue":"2","key":"2081_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/IGC.0000000000000058","volume":"24","author":"R Michaelson-Cohen","year":"2014","unstructured":"Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233\u20137.","journal-title":"Int J Gynecol Cancer."},{"issue":"6","key":"2081_CR39","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.fertnstert.2013.01.109","volume":"99","author":"A Finch","year":"2013","unstructured":"Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724\u20138.","journal-title":"Fertil Steril"},{"issue":"31","key":"2081_CR40","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1200\/JCO.2013.49.3007","volume":"31","author":"IM Collins","year":"2013","unstructured":"Collins IM, Milne RL, McLachlan SA, et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol. 2013;31(31):3920\u20135. https:\/\/doi.org\/10.1200\/JCO.2013.49.3007.","journal-title":"J Clin Oncol."},{"issue":"8","key":"2081_CR41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/GME.0000000000000633","volume":"23","author":"TC van Tilborg","year":"2016","unstructured":"van Tilborg TC, Broekmans FJ, Pijpe A, et al. Do BRCA1\/2 mutation carriers have an earlier onset of natural menopause? Menopause. 2016;23(8):903\u201310. https:\/\/doi.org\/10.1097\/GME.0000000000000633.","journal-title":"Menopause."},{"issue":"9","key":"2081_CR42","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/cncr.27952","volume":"119","author":"WT Lin","year":"2013","unstructured":"Lin WT, Beattie M, Chen L-M, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1\/2 mutation carriers with a non-clinic- based sample of women in northern California. Cancer. 2013;119(9):1652\u20139.","journal-title":"Cancer"},{"key":"2081_CR43","doi-asserted-by":"publisher","unstructured":"Tomao F, Di Pinto A, Sassu CM, Bardhi E, Di Donato V, Muzii L, Petrella MC, Peccatori FA, Panici PB. Fertility preservation in ovarian tumours. Ecancermedicalscience. 2018;12:885. https:\/\/doi.org\/10.3332\/ecancer.2018.885.","DOI":"10.3332\/ecancer.2018.885"},{"issue":"1","key":"2081_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.fertnstert.2017.12.004","volume":"109","author":"H Daum","year":"2018","unstructured":"Daum H, Peretz T, Laufer N. BRCA mutations and reproduction. Fertil Steril. 2018;109(1):33\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.12.004.","journal-title":"Fertil Steril"},{"issue":"3","key":"2081_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.rbmo.2015.06.010","volume":"31","author":"S Gunes","year":"2015","unstructured":"Gunes S, Al-Sadaan M, Agarwal A. Spermatogenesis, DNA damage and DNA repair mechanisms in male infertility. Reprod Biomed Online. 2015;31(3):309\u201319.","journal-title":"Reprod Biomed Online."},{"issue":"35","key":"2081_CR46","doi-asserted-by":"publisher","first-page":"24617","DOI":"10.1074\/jbc.M114.566141","volume":"289","author":"S Simhadri","year":"2014","unstructured":"Simhadri S, Peterson S, Patel DS, et al. Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. J Biol Chem. 2014;289(35):24617\u201329.","journal-title":"J Biol Chem."},{"key":"2081_CR47","doi-asserted-by":"publisher","first-page":"103201","DOI":"10.1016\/j.critrevonc.2020.103201","volume":"157","author":"P Vukovi\u0107","year":"2021","unstructured":"Vukovi\u0107 P, Peccatori FA, Massarotti C, Miralles MS, Beketi\u0107-Ore\u0161kovi\u0107 L, Lambertini M. Preimplantation genetic testing for carriers of BRCA1\/2 pathogenic variants. Crit Rev Oncol Hematol. 2021;157:103201.","journal-title":"Crit Rev Oncol Hematol."},{"key":"2081_CR48","doi-asserted-by":"publisher","unstructured":"Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks. J Clin Oncol. 2010;28(2):240\u20134. https:\/\/doi.org\/10.1200\/JCO.2009.24.2057.","DOI":"10.1200\/JCO.2009.24.2057"},{"issue":"1","key":"2081_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1933719117728800","volume":"25","author":"V Turan","year":"2018","unstructured":"Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes. Reprod Sci. 2018;25(1):26\u201332. https:\/\/doi.org\/10.1177\/1933719117728800.","journal-title":"Reprod Sci."},{"issue":"3","key":"2081_CR50","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10815-019-01658-9","volume":"37","author":"E Porcu","year":"2020","unstructured":"Porcu E, Cillo GM, Cipriani L, et al. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer. J Assist Reprod Genet. 2020;37(3):709\u201315.","journal-title":"J Assist Reprod Genet."},{"key":"2081_CR51","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.fertnstert.2015.07.1162","volume":"104","author":"M Shapira","year":"2015","unstructured":"Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. BRCA mutation carriers show normal ovarian response in vitro fertilization cycles. Fertil Steril. 2015;104:1162\u20137.","journal-title":"Fertil Steril"},{"issue":"1","key":"2081_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/annonc\/mdx639","volume":"29","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, et al. t'Kint de Roodenbeke MD, de Azambuja E, Ignatiadis M, Demeestere I. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237\u201343.","journal-title":"Ann Oncol."},{"issue":"2","key":"2081_CR53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.fertnstert.2018.10.014","volume":"111","author":"V Gunnala","year":"2019","unstructured":"Gunnala V, Fields J, Irani M, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111(2):363\u201371.","journal-title":"Fertil Steril."},{"key":"2081_CR54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fendo.2019.00235","volume":"10","author":"KA Son","year":"2019","unstructured":"Son KA, Lee DY, Choi D. Association of BRCA Mutations and Anti-m\u00fcllerian Hormone Level in Young Breast Cancer Patients. Front Endocrinol (Lausanne). 2019;10:235. https:\/\/doi.org\/10.3389\/fendo.2019.00235.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2081_CR55","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fonc.2019.00575","volume":"9","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, et al. Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-m\u00fcllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. Front Oncol. 2019;9:575.","journal-title":"Front Oncol"},{"issue":"2","key":"2081_CR56","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/humrep\/dey358","volume":"34","author":"M Grynberg","year":"2019","unstructured":"Grynberg M, Dagher Hayeck B, Papanikolaou EG, Sifer C, Sermondade N, Sonigo C. BRCA1\/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Hum Reprod. 2019;34(2):374\u20139. https:\/\/doi.org\/10.1093\/humrep\/dey358.","journal-title":"Hum Reprod."},{"key":"2081_CR57","doi-asserted-by":"publisher","unstructured":"Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, ESMO Guidelines Committee et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1664\u201378. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.006.","DOI":"10.1016\/j.annonc.2020.09.006"},{"issue":"20","key":"2081_CR58","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2217\/fon-2016-0176","volume":"12","author":"G Bedoschi","year":"2016","unstructured":"Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333\u201344.","journal-title":"Future Oncol"},{"issue":"31","key":"2081_CR59","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2012.47.7893","volume":"31","author":"A Valentini","year":"2013","unstructured":"Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.47.7893 Epub 2013 Aug 26.","journal-title":"J Clin Oncol."},{"issue":"7","key":"2081_CR60","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, Pond\u00e9 NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497\u2013508. https:\/\/doi.org\/10.1093\/annonc\/mdy127.","journal-title":"Ann Oncol."},{"issue":"14","key":"2081_CR61","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.19.03292","volume":"38","author":"N Tung","year":"2020","unstructured":"Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, et al. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020;38(14):1539\u201348.","journal-title":"J Clin Oncol."},{"issue":"12","key":"2081_CR62","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol."},{"key":"2081_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/CCO.0000000000000516","volume":"31","author":"HR Garber","year":"2019","unstructured":"Garber HR, Litton JK. Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. Curr Opin Oncol. 2019;31:247\u201355. https:\/\/doi.org\/10.1097\/CCO.0000000000000516.","journal-title":"Curr Opin Oncol."},{"issue":"8","key":"2081_CR64","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/humrep\/deaa128","volume":"35","author":"AL Winship","year":"2020","unstructured":"Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020;35(8):1864\u201374. https:\/\/doi.org\/10.1093\/humrep\/deaa128.","journal-title":"Hum Reprod."},{"issue":"19","key":"2081_CR65","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","volume":"36","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018;36(19):1981\u201390.","journal-title":"J Clin Oncol."},{"issue":"24","key":"2081_CR66","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1001\/jama.2015.17291","volume":"314","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314(24):2632\u201340.","journal-title":"JAMA"},{"issue":"2","key":"2081_CR67","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/jnci\/djy185","volume":"111","author":"HCF Moore","year":"2019","unstructured":"Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, et al. Final Analysis of the Prevention of Early Menopause Study (POEMS)\/SWOG Intergroup S0230. J Natl Cancer Inst. 2019;111(2):210\u20133.","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"2081_CR68","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","volume":"28","author":"RCF Leonard","year":"2017","unstructured":"Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, et al. Anderson RA; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811\u20136.","journal-title":"Ann Oncol."},{"issue":"1","key":"2081_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/annonc\/mds250","volume":"24","author":"M Wong","year":"2013","unstructured":"Wong M, O'Neill S, Walsh G, Smith IE. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol. 2013;24(1):133\u20138. https:\/\/doi.org\/10.1093\/annonc\/mds250 Epub 2012 Sep 27. PMID: 23019276.","journal-title":"Ann Oncol."},{"key":"2081_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ctrv.2018.11.006","volume":"72","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treat Rev. 2019;72:65\u201377. https:\/\/doi.org\/10.1016\/j.ctrv.2018.11.006.","journal-title":"Cancer Treat Rev."},{"issue":"22","key":"2081_CR71","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","volume":"34","author":"I Demeestere","year":"2016","unstructured":"Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J Clin Oncol. 2016;34(22):2568\u201374. https:\/\/doi.org\/10.1200\/JCO.2015.65.8864.","journal-title":"J Clin Oncol."},{"issue":"2","key":"2081_CR72","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/humrep\/dex356","volume":"33","author":"FA Peccatori","year":"2018","unstructured":"Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33(2):181\u20137. https:\/\/doi.org\/10.1093\/humrep\/dex356.","journal-title":"Hum Reprod."},{"key":"2081_CR73","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.04.009","volume":"57","author":"C Massarotti","year":"2017","unstructured":"Massarotti C, Scaruffi P, Lambertini M, Remorgida V, Del Mastro L, Anserini P. State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. Cancer Treat Rev. 2017;57:50\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2017.04.009.","journal-title":"Cancer Treat Rev."},{"key":"2081_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.breast.2018.08.099","volume":"42","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, et al. The BCY3\/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41\u20139. https:\/\/doi.org\/10.1016\/j.breast.2018.08.099.","journal-title":"Breast."},{"key":"2081_CR75","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3332\/ecancer.2020.1157","volume":"14","author":"B Buonomo","year":"2020","unstructured":"Buonomo B, Peccatori FA. Fertility preservation in endocrine responsive breast cancer: data and prejudices. Ecancermedicalscience. 2020;14:1157. https:\/\/doi.org\/10.3332\/ecancer.2020.1157.","journal-title":"Ecancermedicalscience."},{"key":"2081_CR76","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/humupd\/dmt034","volume":"20","author":"TN Sergentanis","year":"2014","unstructured":"Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:106\u201323.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"2081_CR77","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41416-018-0139-1","volume":"119","author":"IAP Derks-Smeets","year":"2018","unstructured":"Derks-Smeets IAP, Schrijver LH, de Die-Smulders CEM, et al. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1\/2 mutation carriers. Br J Cancer. 2018;119(3):357\u201363.","journal-title":"Br J Cancer."},{"issue":"1-5","key":"2081_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jsbmb.2006.09.004","volume":"102","author":"J Russo","year":"2006","unstructured":"Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006;102(1-5):89\u201396. https:\/\/doi.org\/10.1016\/j.jsbmb.2006.09.004 PMID: 17113977; PMCID: PMC1832080.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"2081_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30371-0","volume":"17","author":"S Tanday","year":"2016","unstructured":"Tanday S. IVF treatment not linked to breast cancer. Lancet Oncol. 2016;17(9):e375. https:\/\/doi.org\/10.1016\/S1470-2045(16)30371-0.","journal-title":"Lancet Oncol."},{"key":"2081_CR80","doi-asserted-by":"publisher","unstructured":"Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 2019;6(6):CD008215. https:\/\/doi.org\/10.1002\/14651858.CD008215.pub3.","DOI":"10.1002\/14651858.CD008215.pub3"},{"key":"2081_CR81","doi-asserted-by":"publisher","unstructured":"Spaan M, van den Belt-Dusebout AW, Lambalk CB, van Boven HH, Schats R, Kortman M, et al. Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology. J Natl Cancer Inst. 2021;113(6):699\u2013709. https:\/\/doi.org\/10.1093\/jnci\/djaa163.","DOI":"10.1093\/jnci\/djaa163"},{"issue":"5","key":"2081_CR82","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","volume":"103","author":"T Perri","year":"2015","unstructured":"Perri T, Lifshitz D, Sadetzki S, et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril. 2015;103(5):1305\u201312.","journal-title":"Fertil Steril."},{"key":"2081_CR83","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994\u20132001.","journal-title":"J Clin Oncol"},{"key":"2081_CR84","doi-asserted-by":"crossref","unstructured":"Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril. 2018;110(3):380\u201386.","DOI":"10.1016\/j.fertnstert.2018.05.034"},{"key":"2081_CR85","doi-asserted-by":"publisher","first-page":"574669","DOI":"10.3389\/fonc.2020.574669","volume":"10","author":"B Bonardi","year":"2020","unstructured":"Bonardi B, Massarotti C, Bruzzone M, Goldrat O, Mangili G, et al. Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:574669. https:\/\/doi.org\/10.3389\/fonc.2020.574669.","journal-title":"Front Oncol."},{"issue":"4","key":"2081_CR86","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1210\/jc.2015-3878","volume":"101","author":"J Kim","year":"2016","unstructured":"Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab. 2016;101(4):1364\u201371.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2081_CR87","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.fertnstert.2020.03.035","volume":"114","author":"IM Dueholm Hjorth","year":"2020","unstructured":"Dueholm Hjorth IM, Kristensen SG, Dueholm M, Humaidan P. Reproductive outcomes after in vitro fertilization treatment in a cohort of Danish women transplanted with cryopreserved ovarian tissue. Fertil Steril. 2020;114(2):379\u201387. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.03.035.","journal-title":"Fertil Steril."},{"issue":"9","key":"2081_CR88","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/aogs.12934","volume":"95","author":"KA Rodriguez-Wallberg","year":"2016","unstructured":"Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, et al. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20\u2009years of multicenter experience. Acta Obstet Gynecol Scand. 2016;95(9):1015\u201326. https:\/\/doi.org\/10.1111\/aogs.12934.","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"2","key":"2081_CR89","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/aogs.13735","volume":"99","author":"EJ Hoekman","year":"2020","unstructured":"Hoekman EJ, Louwe LA, Rooijers M, et al. Ovarian tissue cryopreservation: Low usage rates and high live-birth rate after transplantation. Acta Obstet Gynecol Scand. 2020;99(2):213\u201321. https:\/\/doi.org\/10.1111\/aogs.13735.","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"8","key":"2081_CR90","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/1933719117702251","volume":"24","author":"F Pacheco","year":"2017","unstructured":"Pacheco F, Oktay K. Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. Reprod Sci. 2017;24(8):1111\u201320. https:\/\/doi.org\/10.1177\/1933719117702251.","journal-title":"Reprod Sci."},{"key":"2081_CR91","doi-asserted-by":"publisher","unstructured":"Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2017;34(3):325\u201336. https:\/\/doi.org\/10.1007\/s10815-016-0843-9.","DOI":"10.1007\/s10815-016-0843-9"},{"key":"2081_CR92","doi-asserted-by":"publisher","unstructured":"Segers I, Bardhi E, Mateizel I, et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Hum Reprod. 2020;35(9):2026\u201336. https:\/\/doi.org\/10.1093\/humrep\/deaa175.","DOI":"10.1093\/humrep\/deaa175"},{"issue":"5","key":"2081_CR93","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/aogs.13610","volume":"98","author":"MM Dolmans","year":"2019","unstructured":"Dolmans MM, Cacciottola L, Amorim CA, Manavella D. Translational research aiming to improve survival of ovarian tissue transplants using adipose tissue-derived stem cells. Acta Obstet Gynecol Scand. 2019;98(5):665\u201371. https:\/\/doi.org\/10.1111\/aogs.13610.","journal-title":"Acta Obstet Gynecol Scand."},{"key":"2081_CR94","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/humrep\/deg110","volume":"18","author":"F Shenfield","year":"2003","unstructured":"Shenfield F, Pennings G, Devroey P, Sureau C, Tarlatzis B, Cohen J. ESHRE ethics task force. Taskforce 5: preimplantation genetic diagnosis. Hum Reprod. 2003;18:649\u201351.","journal-title":"Hum Reprod"},{"key":"2081_CR95","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/pd.1925","volume":"28","author":"MJ Jasper","year":"2008","unstructured":"Jasper MJ, Liebelt J, Hussey ND. Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. Prenat Diagn. 2008;28:292\u20138.","journal-title":"Prenat Diagn"},{"key":"2081_CR96","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10549-014-2951-5","volume":"145","author":"IA Derks-Smeets","year":"2014","unstructured":"Derks-Smeets IA, de Die-Smulders CE, Mackens S, van Golde R, Paulussen AD, Dreesen J, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treat. 2014;145:673\u201381.","journal-title":"Breast Cancer Res Treat"},{"key":"2081_CR97","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.midw.2014.09.010","volume":"31","author":"J Cunningham","year":"2015","unstructured":"Cunningham J, Goldsmith L, Skirton H. The evidence base regarding the experiences of and attitudes to preimplantation genetic diagnosis in prospective clients. Midwifery. 2015;31:288\u201396.","journal-title":"Midwifery"},{"issue":"4","key":"2081_CR98","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/humrep\/des441","volume":"28","author":"L Donnelly","year":"2013","unstructured":"Donnelly L, Watson M, Moynihan C, Bancroft E, Evans D, Eeles R, et al. Reproductive decision-making in young female carriers of a BRCA mutation. Human Reproduction. 2013;28(4):1006\u201312.","journal-title":"Human Reproduction"},{"key":"2081_CR99","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/gim.0b013e31822ddc7e","volume":"14","author":"GP Quinn","year":"2012","unstructured":"Quinn GP, Pal T, Murphy D, Vadaparampil ST, Kumar A. High-risk consumers\u2019 perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis. Genet Med. 2012;14:191\u2013200.","journal-title":"Genet Med"},{"issue":"2","key":"2081_CR100","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.rbmo.2017.11.005","volume":"36","author":"JJG Gietel-Habets","year":"2018","unstructured":"Gietel-Habets JJG, de Die-Smulders CEM, Tjan-Heijnen VCG, et al. Professionals' knowledge, attitude and referral behaviour of preimplantation genetic diagnosis for hereditary breast and ovarian cancer. Reprod Biomed Online. 2018;36(2):137\u201344.","journal-title":"Reprod Biomed Online."},{"key":"2081_CR101","first-page":"385","volume":"59","author":"BJ Abbate","year":"2014","unstructured":"Abbate BJ, Klitzman R, Chung WK, Ottman R, Leu CS, Appelbaum PS. Views of preimplantation genetic diagnosis (PGD) among psychiatrists and neurologists. J. Reprod. Med. 2014;59:385\u201392.","journal-title":"J. Reprod. Med."},{"key":"2081_CR102","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejogrb.2009.10.023","volume":"148","author":"GH Caldas","year":"2010","unstructured":"Caldas GH, Caldas E, Ara\u00fajo ED, Bonetti TCS, Leal CB, Costa AM. Opinions concerning pre-implantation genetic diagnosis and sex selection among gynecologist-obstetricians in Brazil. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010;148:158\u201362.","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"6","key":"2081_CR103","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.fertnstert.2010.03.064","volume":"94","author":"GP Quinn","year":"2010","unstructured":"Quinn GP, Vadaparampil ST, Tollin S, Miree CA, Murphy D, Bower B, et al. BRCA carriers\u2019 thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. Fertil Steril. 2010;94(6):2473\u20135.","journal-title":"Fertil Steril"},{"key":"2081_CR104","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/humrep\/dem055","volume":"22","author":"U Menon","year":"2007","unstructured":"Menon U, Harper J, Sharma A, Fraser L, Burnell M, ElMasry K, et al. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod. 2007;22:1573\u20137.","journal-title":"Hum Reprod"},{"key":"2081_CR105","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/humrep\/den471","volume":"24","author":"D Fortuny","year":"2009","unstructured":"Fortuny D, Balmana J, Grana B, Torres A, Ramon y Cajal T, Darder E, et al. Opinion about reproductive decision making among individuals undergoing BRCA1\/2 genetic testing in a multicentre Spanish cohort. Hum Reprod. 2009;24:1000\u20136.","journal-title":"Hum Reprod"},{"issue":"3","key":"2081_CR106","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s10897-016-0035-x","volume":"26","author":"JL Chan","year":"2017","unstructured":"Chan JL, Johnson LNC, Sammel MD, DiGiovanni L, Voong C, Domchek SM, et al. Reproductive Decision-Making in Women with BRCA1\/2 Mutations. J Genet Couns. 2017;26(3):594\u2013603. https:\/\/doi.org\/10.1007\/s10897-016-0035-x.","journal-title":"J Genet Couns."},{"issue":"6","key":"2081_CR107","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1007\/s10897-018-0264-2","volume":"27","author":"P Mor","year":"2018","unstructured":"Mor P, Brennenstuhl S, Metcalfe KA. Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers. J Genet Couns. 2018;27(6):1386\u201394. https:\/\/doi.org\/10.1007\/s10897-018-0264-2.","journal-title":"J Genet Couns."},{"key":"2081_CR108","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.fertnstert.2013.02.043","volume":"100","author":"Ethics Committee of American Society for Reproductive M","year":"2013","unstructured":"Ethics Committee of American Society for Reproductive M. Use of preimplantation genetic diagnosis for serious adult-onset conditions: a committee opinion. Fertil Steril. 2013;100:54\u20137.","journal-title":"Fertil Steril"},{"issue":"11","key":"2081_CR109","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/medethics-2013-101470","volume":"40","author":"T Zuradzki","year":"2014","unstructured":"Zuradzki T. Preimplantation genetic diagnosis and rational choice under risk or uncertainty. J Med Ethics. 2014;40(11):774\u20138. https:\/\/doi.org\/10.1136\/medethics-2013-101470.","journal-title":"J Med Ethics."},{"issue":"6","key":"2081_CR110","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.fertnstert.2019.01.035","volume":"111","author":"M Heijligers","year":"2019","unstructured":"Heijligers M, Peeters A, van Montfoort A, Nijsten J, Janssen E, Gunnewiek FK, et al. Growth, health, and motor development of 5-year-old children born after preimplantation genetic diagnosis. Fertil Steril. 2019;111(6):1151\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.01.035.","journal-title":"Fertil Steril."},{"issue":"2","key":"2081_CR111","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.fertnstert.2019.03.033","volume":"112","author":"WY Zhang","year":"2019","unstructured":"Zhang WY, von Versen-H\u00f6ynck F, Kapphahn KI, Fleischmann RR, Zhao Q, Baker VL. Maternal and neonatal outcomes associated with trophectoderm biopsy. Fertil Steril. 2019;112(2):283\u2013290.e2. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.03.033.","journal-title":"Fertil Steril"},{"key":"2081_CR112","doi-asserted-by":"publisher","unstructured":"Meister U, Finck C, St\u00f6bel-Richter Y, Schmutzer G, Br\u00e4hler E. Knowledge and attitudes towards preimplantation genetic diagnosis in Germany. Hum. Reprod. 2005;20(1):231\u20138. https:\/\/doi.org\/10.1093\/humrep\/deh548.","DOI":"10.1093\/humrep\/deh548"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02081-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:31:06Z","timestamp":1725755466000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02081-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02081-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fedro A Peccatori received honoraria from Roche Diagnostic and Ipsen outside the submitted work. Matteo Lambertini acted as a consultant for Roche, AstraZeneca, Lilly, and Novartis and received speaker honoraria from Sandoz, Roche, Takeda, Pfizer, Lilly, and Novartis outside the submitted work. Fedro A Peccatori received honoraria from Roche Diagnostic and Ipsen outside the submitted work. All the other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}